Amgen’s Phase III data supports FDA label expansion of Repatha
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
India currently hosts more than 10,075 biotech startups
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
Subscribe To Our Newsletter & Stay Updated